A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Must have advanced liver cancer that cannot be treated with surgery or other local
methods

- Liver cancer is confirmed by a microscopic examination of tissue

- Liver disease is classified as 'A' by a standard method called Child-Pugh score

- Daily living abilities are classified as '0 or 1' by a standard method from the
Eastern Cooperative Oncology Group (ECOG)

- Women must use contraception

Exclusion Criteria:

- Prior liver transplant

- Increase in blood pressure in some of the veins entering the liver

- Cancer that has spread to the brain or the layers of tissue that cover the brain or
spinal cord

- Infection with both hepatitis B and C, both hepatitis D and B, infection with HIV, or
other infections

- Disease of the heart or blood vessels around the heart

- Active cancers within the last 2 years

- No more than 2 prior systemic treatments or other investigational agents except
PD-1/PD-L1 or Ipilimumab (Part 2)

- Currently on anti-platelet or anti-coagulation therapy

- Radiotherapy within 4 weeks of treatment

- Any major allergies

Other protocol defined inclusion/exclusion criteria could apply